Semaglutide 3 mg Injection: Does This Dose Actually Exist?

There is no FDA-approved semaglutide 3 mg injection. The highest approved weekly injectable doses are 2 mg for Ozempic and 2.4 mg for Wegovy, and the 3 mg figure actually belongs to Rybelsus, the oral semaglutide tablet taken once a day by mouth. If you see a "semaglutide 3 mg injection" advertised, it is a compounded vial, a mislabeled product, or a listing that mixes up the oral dose with the injected one.

Is There a 3 mg Semaglutide Injection on the Market?

No brand-name semaglutide injection is manufactured in a 3 mg strength. Novo Nordisk makes the injectable forms in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2 mg, and 2.4 mg doses, and the FDA has not approved any of them at 3 mg.

The table below shows where 3 mg does and does not appear across semaglutide products.

Product	Form	Available strengths	Highest approved dose
Ozempic	Weekly injection pen	0.25, 0.5, 1, 2 mg	2 mg weekly
Wegovy	Weekly injection pen	0.25, 0.5, 1, 1.7, 2.4 mg	2.4 mg weekly
Rybelsus	Daily oral tablet	3, 7, 14 mg	14 mg daily
Compounded semaglutide	Vial plus syringe	Varies, often 1–5 mg/mL	Not FDA-approved

Every 3 mg entry in the semaglutide world belongs to the oral tablet line. Rybelsus starts at 3 mg daily, then moves to 7 mg and 14 mg after at least 30 days at each step. It is swallowed with water on an empty stomach, not injected.

Why the "3 mg Injection" Search Exists

Oral tablets get confused with injections

Because both product lines contain the same active ingredient, people often assume the strengths carry over. They do not. An oral tablet and an injection deliver the drug differently, and a 3 mg tablet is not the same thing as a 3 mg shot.

Compounded vials are dosed by volume, not by pen strength

Compounded semaglutide is usually sold as a liquid with a concentration printed on the label, such as 2.5 mg/mL or 5 mg/mL. Someone drawing 0.6 mL from a 5 mg/mL vial is injecting 3 mg, even though no 3 mg branded pen exists. That math is how "3 mg" ends up in injection conversations.

What the Approved Injectable Schedules Actually Look Like

Both FDA-approved injectables use step-up dosing rather than a fixed starting dose.

• Ozempic (type 2 diabetes): 0.25 mg weekly for four weeks, then 0.5 mg, then 1 mg, and 2 mg only if more blood sugar control is needed.
• Wegovy (chronic weight management): 0.25 mg weekly for four weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg over roughly 16 to 20 weeks.

Doctors escalate slowly on purpose. Starting at or jumping to a high dose raises the odds of severe nausea, vomiting, and dehydration, and it does not produce faster results.

Side Effects and Safety Limits

Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, and injection-site reactions. Most ease within a few weeks once the dose is stable.

• Pancreatitis and gallbladder disease have been reported with semaglutide use.
• Semaglutide carries a boxed warning for thyroid C-cell tumors observed in rodents.
• It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
• Semaglutide is not for use during pregnancy and should be stopped before a planned pregnancy.

Anyone considering a dose above the approved label, including a compounded 3 mg injection, should talk with a licensed prescriber first. Doses beyond the labeled range have not been studied the way the approved regimens have.

Compounded Products and Unregulated Peptide Vendors

The FDA declared the semaglutide shortage resolved in early 2025 and told compounding pharmacies to stop making copies of the branded drug, though enforcement and state rules vary. That shift has pushed some buyers toward unregulated vendors selling "research grade" vials with no pharmacy oversight.

Unregulated vials are not guaranteed to contain semaglutide at all, and sterility is not assured. People trade vendor opinions on forums, including places like peptides source reddit, while mixing and dosing questions show up on recon peptides reddit. Those threads are anecdotal and are not evidence of purity or safety.

A certificate of analysis is only as trustworthy as the lab behind it, so reading independent elite peptides reviews and cross-checking results matters more than a polished product page. Sellers of unapproved injectables also carry real legal exposure, and coverage of something like the paradigm peptides lawsuit is a reminder that gray-market injectables are not a low-stakes purchase.

What to Ask a Prescriber Before Injecting

• Which approved strength am I being prescribed, and how many milligrams is each dose?
• What is the titration plan, and how long do I stay at each step?
• Is the product FDA-approved, compounded by a licensed 503A or 503B pharmacy, or something else?
• Which side effects should make me call you right away?

Semaglutide is a genuinely effective medication for many people with type 2 diabetes or obesity when it is used as studied. The strength on the label should always match the dose in the syringe, and a 3 mg injection is not part of any FDA-approved regimen.

COMMON QUESTIONS

Frequently Asked Questions

Is there a 3 mg semaglutide injection?

No. The FDA has not approved any injectable semaglutide at a 3 mg strength. Approved weekly injection doses top out at 2 mg for Ozempic and 2.4 mg for Wegovy. The 3 mg strength belongs to Rybelsus, which is an oral tablet, not a shot.

What is the highest dose of semaglutide injection?

The maximum approved weekly dose is 2 mg for Ozempic and 2.4 mg for Wegovy. Those ceiling doses are reached only after several months of gradual step-ups. Doses above them are not FDA-approved for any injectable semaglutide product.

Why is compounded semaglutide measured in mg/mL?

Compounded semaglutide is a liquid, so the label lists concentration instead of a fixed pen strength. A 5 mg/mL vial contains 5 mg of drug in each 1 mL, meaning 0.6 mL delivers 3 mg. Compounded semaglutide is not FDA-approved and has been restricted since the drug shortage ended.